Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Teva Pharmaceutical Industries stock

Own Teva Pharmaceutical Industries stock in just a few minutes.

Teva Pharmaceutical Industries Limited is a drug manufacturers-specialty & generic business based in the US. Teva Pharmaceutical Industries shares (TEVA) are listed on the NYSE and all prices are listed in US Dollars. Teva Pharmaceutical Industries employs 37,100 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Teva Pharmaceutical Industries

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TEVA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Teva Pharmaceutical Industries share price

Use our graph to track the performance of TEVA stocks over time.

Teva Pharmaceutical Industries shares at a glance

Information last updated 2021-03-10.
52-week range$6.25 - $13.30
50-day moving average $11.59
200-day moving average $10.13
Wall St. target price$12.66
PE ratio 872
Dividend yield $0 (0%)
Earnings per share (TTM) $0.00

Buy Teva Pharmaceutical Industries shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Teva Pharmaceutical Industries stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Teva Pharmaceutical Industries under- or over-valued?

Valuing Teva Pharmaceutical Industries stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Teva Pharmaceutical Industries's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Teva Pharmaceutical Industries's P/E ratio

Teva Pharmaceutical Industries's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 872x. In other words, Teva Pharmaceutical Industries shares trade at around 872x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Teva Pharmaceutical Industries's PEG ratio

Teva Pharmaceutical Industries's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8336. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Teva Pharmaceutical Industries's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Teva Pharmaceutical Industries's EBITDA

Teva Pharmaceutical Industries's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.6 billion.

The EBITDA is a measure of a Teva Pharmaceutical Industries's overall financial performance and is widely used to measure a its profitability.

Teva Pharmaceutical Industries financials

Revenue TTM $16.7 billion
Operating margin TTM 18.34%
Gross profit TTM $7.7 billion
Return on assets TTM 3.53%
Return on equity TTM -31.38%
Profit margin -23.95%
Book value $9.14
Market capitalisation $12.1 billion

TTM: trailing 12 months

Shorting Teva Pharmaceutical Industries shares

There are currently 32.1 million Teva Pharmaceutical Industries shares held short by investors – that's known as Teva Pharmaceutical Industries's "short interest". This figure is 4.9% up from 30.6 million last month.

There are a few different ways that this level of interest in shorting Teva Pharmaceutical Industries shares can be evaluated.

Teva Pharmaceutical Industries's "short interest ratio" (SIR)

Teva Pharmaceutical Industries's "short interest ratio" (SIR) is the quantity of Teva Pharmaceutical Industries shares currently shorted divided by the average quantity of Teva Pharmaceutical Industries shares traded daily (recently around 10.7 million). Teva Pharmaceutical Industries's SIR currently stands at 3.01. In other words for every 100,000 Teva Pharmaceutical Industries shares traded daily on the market, roughly 3010 shares are currently held short.

However Teva Pharmaceutical Industries's short interest can also be evaluated against the total number of Teva Pharmaceutical Industries shares, or, against the total number of tradable Teva Pharmaceutical Industries shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Teva Pharmaceutical Industries's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Teva Pharmaceutical Industries shares in existence, roughly 30 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Teva Pharmaceutical Industries shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Teva Pharmaceutical Industries.

Find out more about how you can short Teva Pharmaceutical Industries stock.

Teva Pharmaceutical Industries's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Teva Pharmaceutical Industries.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Teva Pharmaceutical Industries's total ESG risk score

Total ESG risk: 58.8

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Teva Pharmaceutical Industries's overall score of 58.8 (as at 12/31/2018) is pretty weak – landing it in it in the 76th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Teva Pharmaceutical Industries is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Teva Pharmaceutical Industries's environmental score

Environmental score: 77.02/100

Teva Pharmaceutical Industries's environmental score of 77.02 puts it squarely in the 87th percentile of companies rated in the same sector. This could suggest that Teva Pharmaceutical Industries is a laggard in its sector in terms of its environmental impact, and exposed to a greater level of risk.

Teva Pharmaceutical Industries's social score

Social score: 47.2/100

Teva Pharmaceutical Industries's social score of 47.2 puts it squarely in the 58th percentile of companies rated in the same sector. This could suggest that Teva Pharmaceutical Industries is pretty average in terms of looking after its workforce and social impact.

Teva Pharmaceutical Industries's governance score

Governance score: 65.26/100

Teva Pharmaceutical Industries's governance score puts it squarely in the 81st percentile of companies rated in the same sector. That could suggest that Teva Pharmaceutical Industries is a laggard in its sector in terms of responsible leadership, and exposed to a greater level of risk.

Teva Pharmaceutical Industries's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Teva Pharmaceutical Industries scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Teva Pharmaceutical Industries hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Teva Pharmaceutical Industries Limited was last rated for ESG on: 2019-01-01.

Total ESG score 58.8
Total ESG percentile 76.26
Environmental score 77.02
Environmental score percentile 87.16
Social score 47.2
Social score percentile 58.24
Governance score 65.26
Governance score percentile 80.64
Level of controversy 3

Teva Pharmaceutical Industries share dividends

We're not expecting Teva Pharmaceutical Industries to pay a dividend over the next 12 months.

Have Teva Pharmaceutical Industries's shares ever split?

Teva Pharmaceutical Industries's shares were split on a 2:1 basis on 30 June 2004. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Teva Pharmaceutical Industries shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Teva Pharmaceutical Industries shares which in turn could have impacted Teva Pharmaceutical Industries's share price.

Teva Pharmaceutical Industries share price volatility

Over the last 12 months, Teva Pharmaceutical Industries's shares have ranged in value from as little as $6.25 up to $13.3. A popular way to gauge a stock's volatility is its "beta".

TEVA.US volatility(beta: 1.45)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Teva Pharmaceutical Industries's is 1.4469. This would suggest that Teva Pharmaceutical Industries's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Teva Pharmaceutical Industries overview

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site